The major component of the neuritic plaque cores and cerebrovascular amyloid of the Alzheimer's disease (AD) exists as a component of at least three distinct precursor proteins, referred to as APP695, APP751, APP770. APP is normally metabolized by at least two pathways: one pathway involves cleavage within the AbetaP sequence, thus preventing formation of the amyloid peptide. The second """"""""amyloidogenic"""""""" pathway results in the production of the amyloid peptide. Recent genetic studies showed that certain mutations in the APP gene that result in amino acid substitutions may cause Familial AD. However, it is still not clear whether these mutations cause AD by increasing production of the amyloid peptide or by altering the biological function of the APP protein. Since the structural elements of a biomolecule define both its biological function and its metabolic pathway, determination of the structural characteristics of the APP is important for the elucidation of its role in the development of AD. Research in our laboratory showed that APP exists as the core protein of a chondroitin sulfate proteoglycan (CSPG), ranging in apparent molecular size from 140 to 250 kDa, secreted by a glial cell line. Most of the secreted nexin II form oa APP occurs in the proteoglycan form. We also obtained evidence that the APP proteoglycan is present in human brain and neuroblastoma cells. Proteoglycans are molecules with important biological functions including cell adhesion and migration, cell-cell communication, modulation of growth factor activities and neural patterning. Dysfunction of the CSPG form of APP may contribute to the neuronal degeneration observed in AD. We find two potential chondroitin sulfate glycosaminoglycan (CSG) attachment sites in close proximity to both the N- terminus of the AbetaP sequence of APP and the secretase cleavage site, suggesting that the CSG chains may affect the proteolysis of APP and production of AbetaP. Here we propose to determine the attachment sites and length of the CSG chains, the structure of the carbohydrate residues attached to APP and the role of the APP CSPG in cell adhesion. In addition we will examine the expression of this novel APP form in normal and AD brains and its developmental regulation in rat brain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-15
Application #
6267310
Study Section
Project Start
1998-04-15
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Gandal, Michael J; Haney, Jillian R; Parikshak, Neelroop N et al. (2018) Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 359:693-697
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :

Showing the most recent 10 out of 555 publications